Wai Chun Bio-Technology Limited has scheduled a board meeting for 6 November 2026 at its Hong Kong headquarters. Directors will review and approve the audited annual results for the financial year ended 30 June 2026 and consider a potential final dividend.

Trading in the company’s shares has been halted since 9:00 a.m. on 2 October 2026 and will remain suspended until the FY 2026 results are released. Shareholders and prospective investors are urged to exercise caution when dealing in the company’s securities.

The current board comprises one executive director—Mr. Lam Ka Chun, who is also Chairman and Chief Executive Officer—and three independent non-executive directors: Mr. Wong Po Keung, Mr. Wang Ziniu and Ms. Xu Huiling.